The UK and US have forged a key trade agreement that will ensure no duties on UK drug exports going into the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to raise funding on drugs through the public health system. This commitment secures that duties on these vital exports will be held at zero for a duration of three years.
This agreement is in response to earlier threats to dramatically increase duties on branded drug imports, with figures floated up to double the cost.
"This deal between the UK reinforces the global environment for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. drug exports," a statement declared.
Trade Impact
Pharmaceuticals are one of the Britain's biggest export categories to the US, which is easily the biggest buyer for major British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value made up 17.4% of British export trade in that timeframe.
"This guarantee safeguards employment, increases capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a government official remarked.
Specific UK Commitments
The pact includes several specific commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be restricted at fifteen percent. Last year, repayments were more than 20%.
Industry Background
The deal comes amid a ongoing dispute between the sector and the British authorities over drug pricing and NHS adoption.
This friction were heightened by claims that US customers were charged several times more for the equivalent treatments than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or abandoned, while major funding commitments have been directed toward US facilities.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a percentage of its resources over the last ten years.
